Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Routine tests undertaken by women dropped by 35% in 2020
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
